Your Personal Invitation
ADC Symposium
|
|
December 2, 2020 or December 3, 2020
|
We cordially invite you to participate in our 2020 Technical Symposium to discover enabling technologies and the latest trends in drug development and processing. During this virtual event, industry experts will be presenting the latest progress in ADC and Bioconjugation.
- Learn about advancements in drug development, drug-linker technologies and product characterization.
- Get perspectives on successful strategies for your ADC and bioconjugation programs.
- Tackle today’s challenges and discuss solutions with your peers.
|
|
|
Chair: Dr. Eric Lacoste, Sanofi
Presentations:
- Taming random conjugation: producing monodisperse ADCs from native antibodies, Dr. S. Kolodych, Syndivia
- Clinical-stage GlycoConnect™ technology as a powerful platform to generate ADCs and bispecific antibodies, Dr. R. van Geel, Synaffix
- The benefits of using orthogonal analytics in ADC drug development, Dr. D. Galbraith, Merck KGaA, Darmstadt, Germany
- Payloads to accelerate the ADC clinical path, Dr. D. Goddel, Merck KGaA, Darmstadt, Germany
|
Chair: Dr. Matthias Joehnck, Merck KGaA, Darmstadt, Germany
Presentations:
- MORAb-202, a folate receptor alpha-targeted ADC, loaded with HALAVEN® (eribulin) as payload, Dr. T. Uenaka, Eisai Inc.
- Payloads to accelerate the ADC clinical path, Dr. D. Goddel, Merck KGaA, Darmstadt, Germany
- Engineered Avibodies™ (improved diabodies) precisely loaded with novel ADC payloads that surpass IgG-ADCs in cancer therapy, Dr. P. Hudson, Avipep
- ABL202/LCB71: a ROR1-targeting antibody-drug conjugate for treating TNBC and CLL, Dr. J. Jung, ABL Bio
- The benefits of using orthogonal analytics in ADC drug development, Dr. D. Galbraith, Merck KGaA, Darmstadt, Germany
*The agenda is subject to change.
More details of the webcast can be found on the registration page.
|
|
|
|
